Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Millendo Therapeutics, Inc.

http://millendo.com/

Latest From Millendo Therapeutics, Inc.

Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.

Deals Business Strategies

Soleno Shaken By FDA Demand For Second DCCR Phase III Trial In PWS

The US FDA has asked Soleno to conduct another Phase III Study evaluating its chief asset in Prader-Willi syndrome patients prior to any NDA submission, rattling investors and clouding the company’s prospects.

Clinical Trials Companies

Levo Product Joins List Of Prader-Willi Syndrome Trial Failures

Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.

Rare Diseases Clinical Trials

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Atterocor, Inc.
    • Alize Pharma
    • OvaScience, Inc.
UsernamePublicRestriction

Register